钠-葡萄糖协同转运蛋白2抑制剂与2型糖尿病患者大疱性类天疱疮风险的相关性:一项全国性人群队列研究
本研究基于台湾全民健康保险数据库2007至2018年数据,纳入149 060例接受SGLT2i的糖尿病患者并按1:2匹配未使用SGLT2i的糖尿病患者,经多因素调整后,使用SGLT2i者发生大疱性类天疱疮的风险较低(调整后HR 0.56,95%CI 0.33-0.96)。结论认为接受SGLT2i的患者大疱性类天疱疮风险未增加。
要点
- 接受SGLT2i的糖尿病患者大疱性类天疱疮风险较低(调整后HR 0.56,95%CI 0.33-0.96)。
- 年龄、肾脏疾病、脑血管疾病、癫痫、DPP4i使用及胰岛素使用是大疱性类天疱疮的显著风险因素。
- 作者认为SGLT2i对于有额外风险因素或有大疱性类天疱疮病史的糖尿病患者可能是安全选择。
核心结论
- 接受SGLT2i的患者大疱性类天疱疮风险未增加,SGLT2i对于有额外风险因素或有大疱性类天疱疮病史的糖尿病患者可能是安全选择。
研究设计与样本
- 全国性人群队列研究,参与者来自台湾全民健康保险数据库2007年至2018年数据。
- 共纳入149 060例接受SGLT2i的糖尿病患者,并按1:2匹配未使用SGLT2i的糖尿病患者。
- 多因素分析纳入年龄、性别、糖尿病病程、DPP4i使用、胰岛素使用及选定合并症等因素。
主要发现
- 与对照组相比,使用SGLT2i的患者在调整竞争性死亡后2年累积发病率显著较低。
- 调整潜在混杂因素后,接受SGLT2i的糖尿病患者发生大疱性类天疱疮的风险较低(调整后HR 0.56,95%CI 0.33-0.96)。
- 年龄(HR 1.06)、肾脏疾病(HR 1.79)、脑血管疾病(HR 3.23)、癫痫(HR 3.07)、DPP4i使用者(HR 2.55)及胰岛素使用者(HR 2.56)是大疱性类天疱疮的显著风险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Certain anti-diabetic agents have been linked to the development of bullous pemphigoid (BP). However, the relationship between BP and sodium-glucose co-transporter 2 inhibitors (SGLT2is) remains inconclusive. OBJECTIVE: To investigate the association between SGLT2i usage and BP. METHODS: Participants were recruited from the Taiwan National Health Insurance Database between 2007 and 2018. A total of 149 060 patients with diabetes receiving SGLT2i were matched 1 : 2 with diabetic patients without SGLT2i usage. Factors such as age, sex, duration of diabetes condition, DPP4i usage, insulin usage and selected comorbidities were included in the multivariate analysis. RESULTS: Compared with the control, the 2-year-cumulative incidence was significantly low in patients using SGLT2i after adjustment for competing mortality. Patients with diabetes receiving SGLT2i had a low risk [adjusted hazard ratio (HR) 0.56, 95% confidence interval (CI), 0.33-0.96] for BP after adjustment for potential confounders. Age (HR, 1.06), renal disease (HR, 1.79), cerebrovascular disease (HR, 3.23), epilepsy (HR, 3.07), DPP4i users (HR: 2.55) and insulin users (HR: 2.56) were significant risk factors for BP. CONCLUSIONS: The risk of BP did not increase in patients receiving SGLT2i. Thus, SGLT2i could be a safe choice for patients with diabetes having additional risk factors or a history of BP.
引用
- Ma SH, Wu CY, Lyu YS, et al. Association between sodium-glucose co-transporter 2 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a nationwide population-based cohort study. J Eur Acad Dermatol Venereol. 2022. PMID: 35344615. doi:10.1111/jdv.18106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。